Economic Evaluation of Andexanet Versus Prothrombin Complex Concentrate for Reversal of Factor Xa-Associated Intracranial Hemorrhage
Stroke 52:1390-1397, Micieli, A.,et al, 2021
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared with Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation
Stroke 49:1464-1470, Reddy, V.Y.,et al, 2018
Oral Anticoagulants for Prevention of Stroke in Atrial Fibrillation: Systematic Review, Network Meta-Analysis, and Cost Effectiveness Analysis
BMJ 359:J5058, Lopez-Lopez, J.A.,et al, 2017
Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients
Stroke 47:1555-1561, Shah, A.,et al, 2016
Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
Stroke 44:1676-1681, Harringotn, A.,et al, 2013
Cost-Effectiveness of Dabigatran Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack
Stroke 43:881-883, Kamel,H.,et al, 2012
Cost Efficiency of Anticoagulation With Warfarin to Prevent Stroke in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation
Stroke 42:112-118, Mercaldi,C.J.,et al, 2011
Cost Effectiveness of Warfarin Versus Aspirin in Patients Older Than 75 Years With Atrial Fibrillation
Stroke 42:1717-1721, Jowett, S.,et al, 2011
Cost-effectiveness of disease-modifying therapy for multiple sclerosis
Neurol 77:355-363, Noyes, K.,et al, 2011
Dabigatran Etexilate versus Warfarin in Management of Non-Valvular Atrial Fibrillation in UK Context: Quantitative Benefit-Harm and Economic Analyses
BMJ 343:d6333, Pink, J.,et al, 2011
Effect of Urgent Treatment of Transient Ischaemic Attack and Minor Stroke on Early Recurrent Stroke (EXPRESS Study): A Prospective Population-Baed Sequential Comparison
Lancet 370:1432-1442,1398, Rothwell,P.M., et al, 2007
Costs and Effectiveness of Ximelagatran for Stroke Prophylaxis in Chronic Atrial Fibrillation
JAMA 293:699-706, OBrien,C.L. &Gage,B.F., 2005
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Effectiveness and Cost?
JNNP 70:574-579, Bryan,J.,et al, 2001
Yield of Diffusion-Weighted MRI for Detection of Potentially Relevant Findings in Stroke Patients
Neurol 54:1562-1567,1548,1549,1552, Albers,G.W.,et al, 2000
Recommendations for the Management of Patients with Unruptured Intracranial Aneurysms
Stroke 31:2742-2750, Bederson,J.B.,et al, 2000
Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics
Arch Neurol 56:1079-1084, Rudick,R.A., 1999
Population Based Cost Utility Study of Interferon Beta-1b in Secondary Progressive Multiple Sclerosis
BMJ 319:1529-1533, Forbes,R.B.,et al, 1999
Imaging the Brain, Part 1 & 2
NEJM 338:812-820, 889-8961998., Gilman,S., 1998
Cost-Effectiveness of Anticoagulation in Nonrheumatic A Fib in the Primary Prevention of Ischemic Stroke
Stroke 29:1827-1832, Lightowlers,S.&McGuire,A., 1998
A Comparison of Rectal Diazepam Gell and Placebo for Acute Repetitive Seizures
NEJM 338:1869-1875, 19161998., Dreifuss,F.E.,et al, 1998
Tolterodine for Overactive Bladder
The Medical Letter 40:101-102, , 1998
Treating Repetitive Seizures with a Rectal Diazepam Formulation,A Randomized Study
Neurol 51:1274-1282, Cereghino,J.J.,et al, 1998
Comparison of an Anticoagulation Clinic With Usual Medical Care: Anticoagulation Control, Patient Outcomes, and Health Care Costs
Arch Int Med 158:1641-1647, Chiquette,E.,et al, 1998
Glatiramer Acetate for Relapsing Multiple Sclerosis
The Medical Letter 39:61-62, , 1997
Intravenous Immune Globulin Therapy for Neurologic Diseases
Ann Int Med 126:721-730, Dalakas,M.C., 1997
The Quality-of-Life Effects of Interferon Beta-1b in MS
Arch Neurol 54:1475-1480, Schwartz,C.E.,et al, 1997
Echocardiographic Identif of Cardiovascular Sources of Emboli to Guide Clin Manag of Stroke:Cost-Effec Analysis
Ann Int Med 127:775-787, McNamara,R.L.,et al, 1997
Problems with Myofascial Pain Syndrome and Fibromyalgia Syndrome
Neurol 46:593-597, Bohr,T., 1996
Interferon Beta in Multiple Sclerosis
BMJ 313:1159, 1157, 1195996., Richards,R.G., 1996
New Antiepileptic Drugs:A Systematic Review of Their Efficacy and Tolerability
BMJ 313:1169-1174, 1157, 1158996., Marson,A.G.,et al, 1996
Long Term Use of Lamotrigine & Vigabatrin in Severe Refractory Epilepsy:Audit of Outcome
BMJ 313:1184-1185, 11571996., Walker,M.C.,et al, 1996
Rational Polypharmacy in the Treatment of Epilepsy
(Ed) , Neurol (suppl) 45:S1-S38., Wilder,B.J., 1995
Cost-Effectiveness of Warfarin and Aspirin for Prophylaxis of Stroke in Patients with Nonvalvular Atrial Fibrillation
JAMA 274:1839-1845, Gage,B.F.,et al, 1995
The Hidden Costs of Medicolegal Abuses in Neurology
Arch Neurol 51:650-652, Scheinberg,P., 1994
The Role of Epilepsy Centers in Delivering Care to Patients with Intractable Epilepsy
Neurol 44:1347-1352, Lesser,R.P., 1994
Update on Surgical Treatment of the Epilepsies, Second Intern Palm Desert Conf on Surgical Trtm of Epilepsies (1992)
Neurol 43:1612-1617, Engel,J.Jr., 1993
Cost Effectiveness of Primary Stroke Prevention in Atrial Fibrillation
BMJ 305:1457-1460, 14451992., Gustafsson,C.,et al, 1992